Previous 10 | Next 10 |
home / stock / amlx / amlx articles
NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amyly...
NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims...
Tuesday, Seelos Therapeutics Inc (NASDAQ:SEEL) provided an update on top-line data of the Phase 2/3 HEALEY ALS Platform trial. ...
SAN FRANCISCO, March 13, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investors who suffered substant...
NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Amylyx Pharmaceuticals, Inc. ("Amylyx" or t...
NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in...
NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds inves...
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite dipping around 0.5% on Friday. The Dow traded up 0.27% to 38,894.21 w...
Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the company reported fourth-quarter financial r...
News, Short Squeeze, Breakout and More Instantly...
Amylyx Pharmaceuticals Inc. Company Name:
AMLX Stock Symbol:
NASDAQ Market:
Amylyx Pharmaceuticals Inc. Website:
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in a fireside chat presentation at the Goldman Sachs 45th Annual Global Healthcare Conference. The conference is being conducted in-person in Miam...
2024-05-10 16:30:03 ET H.C. Wainwright analyst issues BUY recommendation for AMLX on May 10, 2024 02:01PM ET. The previous analyst recommendation was Buy. AMLX was trading at $1.775 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...